A comparative study of clinico-functional outcomes of intraarticular Platelet Rich Plasma and Platelet Rich Fibrin in the management of early osteoarthritis of knee – prospective randomized control trial

SL.

PARTICUARS

COMMENTS

|1.

Name of the PG student

DR. ANKIT

|2.

Name of the Guide

DR. HARIPRASAD S.

|3.

Title of the Topic

A COMPARATIVE STUDY OF CLINICO-FUNCTIONAL OUTCOMES OF INTRAARTICULAR PLATELET RICH PLASMA AND PLATELET RICH FIBRIN IN THE MANAGEMENT OF EARLY OSTEOARTHRITIS OF KNEE – PROSPECTIVE RANDOMIZED CONTROL TRIAL

|4.

Need for the study

PRP exerts its therapeutic mechanism via growth factors stored in the α-granule of platelets. Platelet-rich plasma has been proven to decrease inflammation, produce high-quality synovial fluid, and reconstruction of degenerative cartilage but its efficacy is yet be proven in conditions like osteoarthritis for long term results.

PRF showed promising properties in connective tissue regeneration and it is now widely applied in chronic wound healing and degenerative conditions. Patient treated with PRF showed better pain control and more persistent pain relief in short and mid-term than those treated with platelet rich plasma.

At present many studies have been done to examine the effectiveness of PRP and PRF individually, but a comparative study with a long term follow-up is yet to be performed.

|5.

Objectives of the study

·       To assess the clinico-functional outcomes of intra-articular injection of PRP in early OA knee using Visual Analogue Scale (VAS) and Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) at pre-procedure, post-procedure, 2nd, 4th, 8th, 12th, 24th weeks respectively.

·       To assess the clinico-functional outcomes intra-articular injection of PRF in early OA knee using VAS and WOMAC Osteoarthritis Index at pre-procedure, post-procedure, 2nd, 4th, 8th, 12th, 24th weeks respectively.

·       To compare clinico-functional outcomes intra-articular injection of PRP vs PRF in early OA knee knee using VAS and WOMAC Osteoarthritis Index at pre-procedure, post-procedure, 2nd, 4th, 8th, 12th, 24th weeks respectively.

  |7.

Material and Methods

STUDY DESIGN:

 A prospective comparative randomized control trial.

 To avoid patient selection bias patients will be grouped into two groups.  Patients will be randomly selected as per the randomization list generated by www.randomizer.org .

  |8.

Method of collection data including sampling procedure

SOURCE OF DATA:

A comparative prospective study will be conducted at R.L Jalappa hospital and research center attached to Sri Devaraj Urs Medical college, affiliated to SDUAHER, from MAY 2024 to OCTOBER 2024. 126 patients with early Osteoarthritis of knee will be included in the study.

After full filling the inclusion criteria and exclusion criteria, informed and written consent will be obtained from all patients who agree to be a part of the study

Patients will be divided into 2 groups

•        Group A included 63 patients who were treated with intra-articular Platelet Rich Plasma injection

•        Group B included 63 patients who were treated with intra-articular Platelet rich fibrin injection.

 INCLUSION CRITERIA:

·       Patients of either gender, aged between 45 to 70 years

·       Patients with early OA knee and Kellgren and Lawrence Scale (K&L) stage I and II

·       Patient with persistent symptoms (pain, joint stiffness etc) irrespective of being treated with conservative treatment, including physical therapy, manipulation

·       Patients were not under any other treatments for Osteoarthritis in the last month besides occasional analgesics

EXCLUSION CRITERIA:

·       Patients with severe osteoarthritis (K&L stage III and IV)

·       Patients treated with long release corticosteroids infiltration over the last month

·       Patients on immune suppressor or chemotherapy treatments

·       Acute rheumatoid arthritis and rheumatoid immune diseases

·       Local/general infections; patients with previous joint replacement

·       Low platelets (<100.000) or low fibrinogen